O059 Efficacy and safety of embolo-sclerotherapy of arteriovenous malformation based on the experience from a single specialist centre

Abstract Introduction To evaluate the efficacy and safety of EST, particularly foamed STS 3% in treatment arteriovenous malformations (AVMs) a single specialist centre. Methods All patients with AVMs who underwent EST from 01 January 2015–31 December 2019 were retrospectively reviewed. Types AVM grouped into Schobinger's classification. ESTs performed either foam sclerosants (STS polidocanol), ethanol, coils and/or other substances including Onyx Gelfoam. Outcome measures included effects complications. Continuous variables compared using ANOVA F test. Other discrete Chi-squared tests. Differences considered significant at p<0.05. Results A total 65 AVMs, mean age 36 years (range 1–74 years) included. The Type IV significantly (p=0.014) higher than others. use was lower for type (0.0%) (p=0.003). Complications III (21.1%)) (p=0.009). 6 (9.2%) experienced complications example, upper lip necrosis partial facial weakness. number days follow-up not different across all types AVM. However, II showed (p=0.038). Conclusion particular sclerotherapy 3%, clinically effective safe to treat This study that may be used as an alternative ethanol AVMs. Take-home message